

UCSF

UC San Francisco Previously Published Works

Title

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Permalink

<https://escholarship.org/uc/item/4rt599d3>

Journal

Clinical Cancer Research, 26(19)

ISSN

1078-0432

Authors

Uppaluri, Ravindra
Campbell, Katie M
Egloff, Ann Marie
et al.

Publication Date

2020-10-01

DOI

10.1158/1078-0432.ccr-20-1695

Peer reviewed



Published in final edited form as:

Clin Cancer Res. 2020 October 01; 26(19): 5140–5152. doi:10.1158/1078-0432.CCR-20-1695.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

Ravindra Uppaluri^{1,2,*,#}, Katie M. Campbell^{3,4,*}, Ann Marie Egloff¹, Paul Zolkind⁵, Zachary L. Skidmore⁴, Brian Nussenbaum^{5,6}, Randal C. Paniello^{5,6}, Jason T. Rich^{5,6}, Ryan Jackson^{5,6}, Patrik Pipkorn^{5,6}, Loren P. Michel^{6,7}, Jessica Ley⁷, Peter Oppelt^{6,7}, Gavin P. Dunn^{6,8}, Erica K. Barnell^{3,4}, Nicholas C. Spies⁴, Tianxiang Lin⁵, Tiantian Li⁹, David T. Mulder⁹, Youstina Hanna⁹, Iulia Cirlan⁹, Trevor J. Pugh^{9,10,11}, Tenny Mudianto², Rachel Riley², Liye Zhou², Vickie Jo¹, Matthew Stachler¹², Glenn J. Hanna², Jason Kass^{1,2}, Robert Haddad^{1,2}, Jonathan D. Schoenfeld^{2,13}, Evisa Gjini¹², Ana Lako¹², Wade Thorstad^{6,14}, Hiram A. Gay^{6,14}, Mackenzie Daly^{6,14}, Scott J. Rodig^{12,15}, Ian S. Hagemann¹⁶, Dorina Kallogjeri⁵, Jay F. Piccirillo^{5,6}, Rebecca D. Chernock¹⁶, Malachi Griffith^{3,4,6,7}, Obi L. Griffith^{3,4,6,7,#}, Douglas R. Adkins^{6,7,#}

¹Department of Surgery, Brigham and Women's Hospital; Boston, MA, USA

²Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA

³Department of Genetics, Washington University School of Medicine; St. Louis, MO, USA

⁴McDonnell Genome Institute, Washington University School of Medicine; St. Louis, MO, USA

⁵Department of Otolaryngology, Washington University School of Medicine; St. Louis, MO, USA

⁶Alvin J. Siteman Cancer Center, Washington University School of Medicine; St. Louis, MO, USA

⁷Department of Medicine/Medical Oncology, Washington University School of Medicine; St. Louis, MO, USA

⁸Department of Neurological Surgery, Washington University School of Medicine; St. Louis, MO, USA

⁹Princess Margaret Cancer Center, University Health Network; Toronto, Ontario, Canada

¹⁰Department of Medical Biophysics, University of Toronto; Toronto, Ontario, Canada

To whom correspondence should be addressed: Dr. Ravindra Uppaluri, Address: 450 Brookline Avenue, Boston, MA, 02215, Telephone: 617-632-3091 Fax: 617-732-6006, Ravindra_Uppaluri@DFCI.harvard.edu.

*Equal contribution

#Co-senior authors

Current Affiliations:

Katie M. Campbell, Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles; Los Angeles, CA, USA

Author Contributions: DRA and RU wrote the clinical study design. BN, RCP, JTR, RJ, PP, LPM, PO, GJH, RH, JDS, JK, WT, HAG, MD, DRA and RU recruited and treated participants. PZ, JL, GPD, EKB, NCS, TL, DTM, YH, IC, TJP, TM, RR, LZ, EG, and AL collected data including clinical outcomes, sample acquisition and processing including for genomic analysis. MS, SJR, VJ, ISH and RDC completed all pathologic assessments. DK and JFP completed all clinical related statistical analysis. KMC, AME, MG, OLG, DRA and RU designed the figures and did the data analysis. RU, DRA, KMC and OLG wrote the first draft of the manuscript, and all authors revised it critically and approved the final version.

¹¹Ontario Institute for Cancer Research; Toronto, Ontario, Canada

¹²Department of Pathology, Brigham and Women's Hospital; Boston, MA, USA

¹³Department of Radiation-Oncology, Brigham and Women's Hospital; Boston, MA, USA

¹⁴Department of Radiation-Oncology, Washington University School of Medicine; St. Louis, MO, USA

¹⁵Center for Immuno-Oncology, Brigham and Women's Hospital; Boston, MA, USA

¹⁶Department of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA

Abstract

Purpose: Pembrolizumab improved survival in recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC) patients. The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)-unrelated HNSCC.

Patients and Methods: Neoadjuvant pembrolizumab (200 mg) was administered and followed 2–3 weeks later by surgical tumor ablation. Post-operative (chemo) radiation was planned. High-risk pathology patients (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10–49%), and pTR-2 (< 50%). Co-primary endpoints were pTR-2 among all patients and one-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 and T-cell infiltration with pTR were assessed. Tumor clonal dynamics were evaluated ([ClinicalTrials.gov NCT02296684](https://clinicaltrials.gov/ct2/show/study/NCT02296684)).

Results: Thirty-six patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3–4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). One-year relapse rate among eighteen patients with high-risk pathology was 16.7% (95% CI: 3.6–41.4%). pTR 10% correlated with baseline tumor PD-L1, immune infiltrate, and IFN- γ activity. Matched samples showed upregulation of inhibitory checkpoints in patients with pTR-0, and confirmed clonal loss in some patients.

Conclusions: Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The one-year relapse rate in patients with high-risk-pathology was lower than historical.

Keywords

neoadjuvant; immunotherapy; pembrolizumab

INTRODUCTION

Patients with head and neck squamous-cell carcinoma (HNSCC) usually present with locally advanced disease. Surgery or definitive (chemo)radiation is the initial treatment in many of these patients. A large subset of surgically treated patients have high-risk pathology features (positive margin and/or extranodal extension) that are best treated with intensive post-operative adjuvant cisplatin and radiation therapy (POACRT). However, 35% of patients, particularly those with human papillomavirus (HPV)-unrelated HNSCC, will develop relapse of disease.(1,2) Attempts to improve this outcome have been unsuccessful.(3) Novel treatment strategies are needed for these patients.

Immune checkpoint inhibitors could reduce the risk of disease relapse in resectable locally advanced, HPV-negative HNSCC. Randomized trials showed that pembrolizumab and nivolumab, inhibitors of the programmed death receptor-1 (PD-1), improved overall survival (OS) of patients with platinum-resistant HNSCC.(4,5) Pembrolizumab given alone or with chemotherapy improved the OS of patients with untreated recurrent or metastatic disease.(6) The results of these trials provide strong rationale for evaluating the clinical impact of immune checkpoint inhibitors in patients with resectable locally advanced, HPV-unrelated HNSCC.

Immunotherapy may be administered before (neoadjuvant) or after (adjuvant) surgery. Pre-clinical experiments with several cancer types showed that administration of immunotherapy in the neoadjuvant interval provided greater benefit than when given in the adjuvant interval.(7–9) In mouse models of spontaneously metastatic breast cancer, neoadjuvant immunotherapy and surgery were more effective in generating tumor-specific CD8+ T-cells and preventing development of lethal metastases than surgery alone.(7,8) Importantly, the benefit of immunotherapy was dependent on resection of the primary tumor. In syngeneic mouse models of HPV-unrelated oral cavity carcinoma with defined T-cell antigens, administration of PD-1 inhibitor before, but not after, surgery reversed functional immunodominance, and induced effector T-cell immunity that resulted in rejection of tumor re-challenge after surgery.(9) Collectively, these data support the critical importance of coordinating administration of immunotherapy before surgery to achieve optimal disease control with this novel strategy.

In addition to improved disease control, administration of immune checkpoint inhibitors in the neoadjuvant interval could result in other clinical benefits, including reduction of the rate of high-risk pathology and downstaging of the cancer. These outcomes could alter the selection of adjuvant therapy, resulting in less intense treatment. Finally, matched tumor tissue obtained at baseline and at surgery can be evaluated to define biomarkers that predict tumor response and resistance to immune checkpoint inhibitors. HNSCC is ideally suited for testing the effect of administration of immune checkpoint inhibitors in the neoadjuvant interval. Tumor is readily accessible to obtain matched baseline and surgical tissue, and to perform visual assessments of tumor response.(10) Although reported in a few other cancers (11–20), the safety and biologic and clinical effects of administration of immune checkpoint inhibitors have not been reported in a patient cohort with resectable locally advanced HPV-unrelated HNSCC.

In this multicenter, phase 2 trial, we aimed to determine if administration of neoadjuvant pembrolizumab to patients with resectable locally advanced, HPV-unrelated HNSCC would be safe and result in pathologic tumor responses (pTR). We evaluated the immunologic correlates to pTR and assessed tumor clonal dynamics in matched tumor samples obtained before and after neoadjuvant pembrolizumab. Among patients with high-risk pathology, we aimed to determine if administration of neoadjuvant and adjuvant pembrolizumab would result in a relapse rate lower than historical. Herein, we report the results of our trial.

PATIENTS AND METHODS

Study Design and Participants

We did a multicenter, phase 2 trial at two university sites in the USA: Washington University, St. Louis, MO and Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. The protocol is included in Supplementary Materials. The trial is a non-randomized two-group study. Patient selection criteria were the same for both groups. Group 1 completed enrollment before Group 2 accrued patients. Group 1 is reported here. In group 1, patients were treated with one dose of neoadjuvant pembrolizumab, followed by surgery. Patients with high-risk pathology were scheduled to be treated with POACRT followed by adjuvant pembrolizumab; patients without high-risk pathology were scheduled to be treated with post-operative adjuvant radiation therapy (POART) or observation but not adjuvant pembrolizumab. In group 2, patients were treated with two doses of neoadjuvant pembrolizumab, followed by surgery, then POACRT if high risk pathology or POART (or observation) if without high-risk pathology. Group 2 did not receive adjuvant pembrolizumab. Group 2 is ongoing, having accrued 25 of the planned sample size of 31 patients; the data are not yet mature. The results of group 2 will be reported at a later date.

Eligible patients had resectable clinical stage III-IVb (AJCC, 7th Edition), HPV-unrelated (oral cavity, larynx, hypopharynx or p16-negative oropharynx) HNSCC, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)v1.1, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and adequate marrow and organ function (absolute neutrophil count 1,500/mcL, platelets 100,000/mcL, hemoglobin 9g/dL; total bilirubin 1.5x upper limits of normal [ULN], AST and ALT 2.5x ULN; serum creatinine 1.5x ULN or creatinine clearance 30 mL/min). Key exclusion criteria included HPV-related oropharynx SCC, active autoimmune disease, or immunodeficiency.

Tests required to determine eligibility included complete blood count, metabolic panel, pregnancy test (women), coagulation and thyroid panels, urinalysis, and CT scans of the neck and chest.

Procedures

In group 1, patients received one dose of pembrolizumab (200 mg, IV) 13–22 days before (neoadjuvant) surgery. Surgery included resection of all gross disease at the primary site, ipsilateral (and contralateral, in some patients) therapeutic/prophylactic neck dissection, and reconstruction using pedicled or free-flap procedures as deemed appropriate. Surgical plan and extent of surgical tumor resection was defined by baseline assessments obtained before

neoadjuvant pembrolizumab and did not change if treatment responses were observed. Patients with high-risk pathology were scheduled to be treated with POACRT, if they had adequate organ function and had recovered from surgery.(1,2) Upon resolution of POACRT-related adverse events (AEs) to grade one and after three months from surgery date, patients with high-risk pathology were scheduled to be treated with adjuvant pembrolizumab (200 mg) every three weeks for six doses. Dose delays of pembrolizumab and treatment of immune-related AEs were performed per protocol. Patients without high-risk pathology (low/intermediate-risk) were scheduled to be treated with POART (or observation), but not adjuvant pembrolizumab. Physician discretion in selection of standard of care adjuvant therapy was permitted in patients with intermediate-risk pathology, such that some patients were treated with POACRT even though they lacked traditional high-risk-pathology. Administration of POA(C)RT was performed per protocol.

Before neoadjuvant pembrolizumab, patients underwent baseline assessment by physical examination and CT scan of the neck, and a biopsy of the primary tumor and collection of peripheral blood for correlative studies. Patients were assessed by physical examination the day before or day of surgery. After patient 20, the trial was amended to perform a CT scan of the neck within ten days prior to surgery. On the day of surgery, tissue from the primary tumor and peripheral blood were collected for correlative studies. AEs were assessed using revised Common Terminology Criteria for Adverse Events (CTCAE)v4.0. Peri-surgical AEs were assessed using Clavien-Dindo Classification of Surgical Complications.(21) Tumor response was assessed using RECISTv1.1. Patients were monitored for 30 days after surgery for AEs and surgical/wound healing complications. During the administration of adjuvant pembrolizumab, patients were assessed every three weeks beginning with the first dose of pembrolizumab by physical examination, complete blood count, and metabolic panel, and every six weeks by thyroid panel and urinalysis. In these patients, AEs were monitored for 90 days after the last dose of adjuvant pembrolizumab. Patients were monitored for relapse every three months after surgery by physical examination and CT scans.

Details of PD-L1 immunohistochemistry (IHC) and multiplex immunofluorescence (MIF) are described in the appendix (see Online). Details regarding whole exome sequencing (WES), performed on tumor samples and matched normal blood, RNA sequencing (RNAseq) on tumor samples, T cell receptor sequencing (CapTCR-seq)(22) on peripheral blood, multisector targeted genome sequencing on tumor samples, and analyses (expression, deconvolution, TCR repertoire, etc.) are provided in the Supplementary Appendix. DNA and RNA data were processed using the Genome Modeling System.(23,24) Sequencing data have been deposited in dbGaP (phs001623). Patient HLA haplotypes and mutational profiles were used to predict putative neoantigens with pVACtools.(25)

Outcomes

The co-primary endpoints were one-year relapse rate (the absolute proportion of patients who developed local-regional and/or distant relapse within one year of surgery) in patients with high-risk pathology, and the proportion of all patients with pTR-2 in the surgical specimen after administration of one dose of neoadjuvant pembrolizumab. pTR was defined as the presence of tumor cell necrosis and keratinous debris with giant cell/histiocytic

reaction, quantified as a percentage of the overall tumor bed (area pathologic response/area pathologic response plus viable tumor): pTR-0 (<10%), pTR-1 (10–49%), and pTR-2 (50–100%). Two pathologists with head and neck expertise (RDC and IH) independently evaluated all slides from baseline and surgery specimens and quantified pTR in increments of 10%. Primary tumor and lymph node metastases were scored separately. Overall pTR was classified based on the best pTR observed in either primary tumor or lymph node. Joint review consensus was reached when discrepancies occurred. Current standardized definitions of immune-checkpoint inhibitor-induced pTR were not available when the study was begun, and were not used in the analysis. Secondary endpoints included safety of administration of neoadjuvant pembrolizumab, and clinical tumor response to neoadjuvant pembrolizumab assessed by physical examination and, in some patients, by RECISTv1.1. Correlative endpoints assessed on matched tumor specimens obtained before and after (on day of surgery) neoadjuvant pembrolizumab included PD-L1 expression, histologic, immunologic, genomic, and tumor clonal dynamic changes. T-cell clonality was performed on peripheral blood obtained before and after neoadjuvant pembrolizumab (Supplementary Table 1).

No major protocol deviations occurred. The protocol was amended six times over the course of the study. Amendments 1–3 included updates of the risk profile and dose modifications of study drug, clarified eligibility criteria, and added Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA as a secondary site. Amendment 4 added correlative studies. Amendment 5 added an unplanned interim analysis after the first 20 patients enrolled into group 1 due to the lower-than-expected rate of patients with high-risk pathology, and added CT scan of the neck to be performed after neoadjuvant pembrolizumab and prior to surgery. Amendment 6 closed accrual to group 1, and added group 2.

Statistics

Relapse rate at one year in patients with high-risk pathology was the initial primary endpoint. Historical data showed that the one-year relapse rate after surgery and POACRT in patients with high-risk pathology was 35%.^(1,2) Relapse rate at one year was selected because the majority (>90%) of relapse events in these patients occurred within one year of surgery.^{1,2} A sample size of 31 evaluable patients was required to detect a reduction in the one-year relapse rate to 20%, with a power of 80%, using a one-sided alpha of 0.05. Evaluable patients for this endpoint were those who had high-risk pathology in the surgical specimen after one dose of neoadjuvant pembrolizumab. Assuming a rate of high-risk pathology of 80% in patients with clinical stage III/IV HPV-unrelated HNSCC, and a 20% drop-out rate, we planned to accrue a total of 46 patients to group 1. However, after enrollment of the first 20 patients, the proportion of patients with high-risk pathology after one dose of neoadjuvant pembrolizumab and surgery was lower than expected (35%), prompting an unplanned interim analysis to assess the feasibility to achieve the initial primary endpoint. Enrollment continued during the interim analysis. The results of the interim analysis confirmed the unexpectedly lower rate of high-risk pathology. The trial was amended to: a) close enrollment of group 1 based on inability to accrue the required number of patients with high-risk pathology in a practical interval, b) addition of pTR-2 after neoadjuvant pembrolizumab in all patients as a co-primary endpoint, and c) addition of

group 2, as previously described. In this report, the analysis of one-year relapse rate in patients with high-risk pathology was performed as intention-to-treat.

Stopping rules were in place for delay of surgery or serious (grade 3–5) AEs attributed to pembrolizumab. The study was to be stopped, and amended or closed, in the event of: 1) neoadjuvant pembrolizumab-related AEs leading to significant delay in surgery (more than 14 days delay in 1 of the first 15 patients, 2 of 30, or 3 of 45) or 2) serious pembrolizumab-related AEs (occurring in 1 of the first 10 patients, 2 of 20, 3 of 30, 4 of 40, or 5 of all patients).

Distribution of demographic and clinical characteristics was defined and compared between patients in high-risk and other (low/intermediate-risk) pathology groups. Percent difference and 95% confidence intervals (CI) were calculated for categorical variables; median difference and 95% CI were calculated for continuous variables. Spearman's rank correlation coefficient was used to estimate correlations between tumor PD-L1 staining and numbers of tumor infiltrating T cells (CD8+ and CD4+) and extent of pTR. Molecular correlates were evaluated for changes across pTR categories using the non-parametric test of trend. Kaplan-Meier estimates of OS, progression-free survival (PFS) and relapse-free survival (RFS) rates and 95% CI by pathology risk category or pTR category were determined and differences between categories assessed using the log rank test. OS was defined as time (months) from day of surgery to death; PFS was defined as time from day of surgery to first disease progression event (new primary, recurrence, distant metastasis or death from disease) or death from any cause; RFS was defined as time from day of surgery to first relapse event (recurrence or distant metastasis). In gene expression analysis, unpaired Mann-Whitney/Wilcoxon rank-sum tests were used to compare the immune cell populations across groups of patients, and paired Wilcoxon signed-rank tests were used to compare matched baseline and post-treatment tumor samples. Differential gene expression analysis was performed using the Wald test across groups.

Study approval

The study protocol was approved by the institutional review board at each participating site and registered nationally ([ClinicalTrials.gov NCT02296684](https://clinicaltrials.gov/ct2/show/study/NCT02296684)). All patients provided written, signed, informed consent to participate. This study followed ethical guidelines of the Declaration of Helsinki, Belmont Report and the US Common Rule. Independent data monitoring was done by the quality assurance committee of Washington University (St. Louis, MO, USA).

Role of the funding source

The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all data in the study. The corresponding author had final responsibility for the decision to submit for publication.

RESULTS

Between June 30, 2015, and March 30, 2018, 36 patients enrolled into group 1 of the trial. Patient and tumor characteristics were typical of those observed in patients with locally

advanced, HPV-unrelated HNSCC: mostly males with a smoking history, and large tumors (Table 1). The trial profile is shown in Figure 1A. All patients received one dose of neoadjuvant pembrolizumab and underwent surgery. Microvascular flap reconstruction was required in 28 patients. Eighteen patients (50%) had high-risk pathology, of which 12 were treated with POACRT and adjuvant pembrolizumab, 4 with POACRT, 1 with POART, and one was observed (Supplementary Table 2). Adjuvant pembrolizumab was not administered to 6 patients with high-risk pathology due to persistent toxicity of POACRT (2), patient decision (2), peri-operative myocardial infarction (1) and interim development of distant metastasis (1). Eighteen patients (50%) had low/intermediate-risk pathology, of which 10 were treated with POART, 4 with POACRT, and 4 were observed.

Administration of neoadjuvant pembrolizumab before surgery was safe. Serious immune-related AEs did not occur in the interval between administration of neoadjuvant pembrolizumab and through 30 days after surgery (Table 2). Unexpected surgical delays or complications were not observed (Supplementary Table 3). Delivery of POACRT was not compromised by prior neoadjuvant pembrolizumab. During administration of adjuvant pembrolizumab, one serious reversible immune-related AE occurred, hypothyroidism (Table 2).

Median follow-up after surgery was 22 months (IQR: 17.1–32.2); 97% had one year follow-up after surgery. In patients with high-risk pathology, the one-year relapse rate was 16.7% (3/18, 95%CI: 3.6–41.4). In patients with low/intermediate-risk pathology, the one-year relapse rate was 0% (Supplementary Figures 1–2).

After neoadjuvant pembrolizumab, pTR-2 occurred in the surgical specimens of 8 patients (22%) and pTR-1 occurred in 8 additional patients (22%). Overall, pTR of 10% was observed in 16 of 36 patients (44%) (Figure 1B, Supplementary Table 4). The proportion of patients who experienced pTR was similar in the high-risk and low/intermediate-risk pathology groups (Figure 1B, Supplementary Table 5). Two patients had major pathologic response (>90%) in both the tumor and lymph nodes but there were no pathologic complete responses. Of the patients with pTR and tumor in the primary site and lymph nodes, 8 of 10 had pTR in only one of these sites.

Significant clinical tumor responses occurred in a minor proportion of patients after neoadjuvant pembrolizumab. Patient 20 experienced an exceptional clinical tumor response, and tumor downstaging (clinical stage IV:T₂N_{2b} downstaged to pathologic stage I:T₁N₀), after neoadjuvant pembrolizumab (Figure 1C–F). The surgical specimen from this patient showed extensive pTR (90%), and only a small residual focus of SCC (Figure 1G). Most patients had stable disease (Figure 1H). The proportion of patients with high-risk pathology (50%) was lower than estimated (80%). Down-staging of cancer (defined as pathologic stage lower than clinical stage) after neoadjuvant pembrolizumab occurred in 7 patients (19%) (Supplementary Table 4).

We explored immunologic correlates of tumor response to neoadjuvant pembrolizumab using IHC, MIF, and RNAseq performed on baseline and surgical samples. A positive correlation existed between PD-L1 protein expression in baseline biopsies and PTR (Figures

2A–B, $r=0.42$; 95%CI: 0.08–0.67; $p=0.02$). MIF showed a positive correlation between extent of PTR and infiltration of CD8+ ($r=0.72$; 95%CI: 0.44–0.88; $p < 0.01$) but not CD4+ T-cells ($r=0.27$; 95%CI: –0.16–0.62; $p=0.20$) in baseline biopsies (Figures 2C–D, Supplementary Figure 3). These immune cell populations were queried by RNAseq(26) and revealed significantly higher levels of overall immune infiltrate, M1 macrophages, and CD4 and CD8 T cells ($p < 0.05$) at baseline in patients with PTR compared to those without (Figure 3, Supplementary Table 7). Consistent with these findings, differential gene expression analysis revealed that patients with PTR ($n=6$) displayed significantly increased baseline expression of immune and inflammatory genes (e.g. *IFNG*, *CXCL9*, *CXCL10*, *CXCL11*, $p < 0.01$, FDR <0.2) as well as significant enrichment of genes associated with these processes ($p < 0.01$, FDR <0.2 , Figure 3A, Supplementary Table 8), compared to patients without PTR ($n=10$). These inflammatory expression patterns were maintained in patients with PTR over treatment ($n=4$).

Interestingly, comparing post-treatment, surgical samples from patients without PTR ($n=11$) to matched baseline samples, post-treatment samples showed enrichment for inflammatory gene signatures ($p < 0.01$, FDR <0.2) and increased expression of T cell checkpoint molecules, including *PDCD1*, *CTLA4*, *ICOS*, *TIGIT*, *IDO1*, and *TNFSF4* ($p < 0.01$, FDR <0.2 , $n=10$, Figure 3D, Supplementary Figure 4, Supplementary Table 8).

TCR sequencing was performed to assess the peripheral blood T cell repertoire relationship to tumor-infiltrating immune-related expression patterns(22). We summarized the TCR repertoire using several metrics associated with either the clonality, richness, or diversity (see Supplementary Methods) (27). There were no significant differences at baseline in the diversity, clonality, and richness in *TRB* clones of peripheral blood between patients without or with PTR. However, patients with PTR exhibited patterns associated with increased TCR diversity and clonality in peripheral blood after neoadjuvant pembrolizumab, with significantly higher Shannon, Gini Simpson, and Inverse Simpson diversity indices and lower geometric coefficient of variance ($p < 0.05$, Supplementary Figures 5–6).(27) Of note, there were 62 *TRA* (0–21 per patient) and 88 *TRB* (0–39 per patient) clonotypes that were also observed in bulk tumor RNAseq data; these tumor-associated clones all ranked in the top 30.6% of clones detected in the peripheral blood (Supplementary Figure 7).

We completed whole exome sequencing (WES) of DNA for 24 baseline and 22 surgical samples (25 patients, 21 matched pairs, average 91.3X coverage). Baseline tumor biopsies had nonsynonymous tumor mutation burden (TMB) ranging from 0.63–5.18 mutations/Mb (30–280 mutations), and the corresponding mutational landscape was consistent with that previously reported for HPV-unrelated HNSCC (Supplementary Figure 8, Supplementary Table 9).(28) Neoantigens were predicted for each patient based upon their mutations(25) and inferred HLA haplotypes(29). Baseline, neoantigen burden ranged from 0–163 (median 76) mutations. Baseline TMB and predicted neoantigen burden did not correlate with extent of PTR ($r=-0.27$, $p=0.2$ and $r=-0.23$, $p=0.29$, respectively; Figure 3).

Comparing matched baseline and post-treatment tumor DNA, there were 2,431 variants (9–260 per patient, $n=22$ patients with matched timepoints) that were detected in both baseline and post-treatment samples, and 873 variants (2–116 per patient) that were detected

uniquely at a single timepoint (Supplementary Figure 9) Variants detected solely at baseline could potentially indicate the event of immune rejection and clonal loss, while the emergence of variants post-treatment could indicate clonal expansion of a non-responsive tumor clone or the presence of *de novo* tumor subclones. However, we hypothesized that some of these clonal dynamics may be observed due to insufficient sequencing depth or sampling bias. To address the impact of sequencing depth on the observed clonal dynamics, we designed a targeted capture probeset on WES-defined mutations (mean 160X coverage) to achieve higher sequencing depth (mean 1,060X coverage). Higher depth sequencing recovered 192 variants that were originally found at only one timepoint by WES, but, there were still 615 variants (0–94 per patient) detected uniquely pre- or post-treatment (Supplementary Figure 9). Of note, clonal loss was not statistically significantly associated with pTR-1/2 ($p=0.63$).

Alternatively, if the baseline and post-treatment surgical sections came from different regions of the tumor, spatial heterogeneity could also explain the presence of variants at either timepoint. While additional baseline samples were unavailable, we performed multisector analysis by micro-dissecting surgical resection samples. FFPE-preserved tumor sections from 8 patients (41 samples, 3–8 per patient, Supplementary Figure 10), obtained from geographically distinct regions in all remaining tumor blocks, were subjected to high-depth DNA sequencing using the custom capture probeset. Four patterns of tumor clonal dynamics were observed across the multisector analysis: (1) clonal conservation confirmed, (2) clonal loss confirmed, (3) clonal loss invalidated, and (4) clonal expansion variable in some or all regions surveyed.

In some patients, mutations were conserved in baseline samples and across all post-treatment sections (e.g. Patient 2, Figure 4). To confirm clonal loss, variants identified as pre-treatment-specific had to be completely absent in all regions of the post-treatment resected surgical specimen. There were 2–71 (median 6.5) variants completely undetected in the original post-treatment specimens (denoted ‘PT1’) across the 8 patients with multi-sector sequencing, which was confirmed for 1–34 (median 3) variants across all available matched post-treatment specimens. Clonal loss was especially evident in Patients 15 (yellow cluster, Supplementary Figure 11) and 16 (purple cluster, Figure 4). On the other hand, there were 2–37 (median 6) variants recovered in at least one post-treatment sample, invalidating some original observations of clonal loss. For example, in Patient 10 (pTR-2, orange and gold clusters, Figure 4), an *NRAS* G13C activating mutation (42.4% baseline DNA VAF) was recovered in 2/6 additional samples (PT6–7).

In the original set of samples, there were 0–25 (median 5.5) variants that were absent at baseline, suggesting the expansion of a novel or previously undetected subclone in 7 patients. Clonal expansion patterns were validated across all post-treatment regions in Patients 1 (pink cluster) and 15 (gold cluster, Supplementary Figure 11), but there were 4–49 variants (median 33) detected in only a subset of regions. These observations suggest that conclusions related to novel subclones or expansion are dependent upon spatial heterogeneity and sampling bias. For example, if PT3 or PT4 had originally been chosen for WES from Patient 16, the clonal expansion observed in PT1 would not have been observed (see pink cluster, Figure 4). Furthermore, since there was spatial heterogeneity post-

treatment, there is strong evidence that this heterogeneity also existed at baseline. Therefore we cannot discount the possibility that apparent clonal expansions might be invalidated if spatial heterogeneity at baseline could be assessed.

DISCUSSION

To the best of our knowledge, we report the first application of an immune checkpoint inhibitor as a therapeutic strategy in patients with locally advanced, HPV-unrelated head and neck cancer. Administration of neoadjuvant pembrolizumab was safe, and did not adversely affect the outcomes of surgery or the delivery of POACRT. Adjuvant pembrolizumab administered to patients with high-risk pathology was associated with a low risk of serious pembrolizumab-related AEs (8%).

In patients with locally advanced, HPV-unrelated HNSCC with high-risk pathology, we hypothesized that pembrolizumab administered before and after surgery would lower the rate of relapse. In our trial, the one-year relapse rate in the 18 patients with high-risk-pathology was 16.7%, lower than the historical rate of 35%.^{1,2} These results should be cautiously interpreted because the sample size was small and the upper limit of the 95% CI for one-year relapse rate included the historical relapse rate. An ongoing international phase 3 trial is testing the potential benefit of neoadjuvant and adjuvant pembrolizumab in patients with resectable, locally advanced HNSCC ([NCT03765918](#)).

In our trial, pTR-1 and pTR-2 occurred in 44% of patients after a single dose of neoadjuvant pembrolizumab. Patients with pTR 10% had better RFS compared to those without pTR. Although the sample size was small, these data provide the first evidence in patients with locally advanced HNSCC that pTR in response to neoadjuvant pembrolizumab may be a biomarker predictive of a lower rate of disease relapse. This hypothesis is being tested in an ongoing, phase 3 trial ([NCT03765918](#)). Pathologic complete response (pCR: absence of tumor in the surgical specimen) after one dose of neoadjuvant pembrolizumab did not occur. pCR rates of 15–45% were reported in other cancers(11–14); however, these trials administered multiple doses of one or combinations of immune checkpoint inhibitors. Discordant primary tumor and lymph node pTR was observed but the biologic mechanism and clinical relevance of this finding are unclear.

We report the most comprehensive evaluation of tumor clonal loss following neoadjuvant immunotherapy, based upon high-depth and multisector genome sequencing of surgical specimens. Two prior studies suggested clonal loss after immunotherapy, but our study showed that depth of genome sequencing and spatial heterogeneity may influence the interpretation of clonal dynamics.(30,31) Clonal loss could be described in 19 cases using traditional WES approaches; five of these patients exhibited pTR. Targeted, high-depth sequencing recovered variants that were not detected by WES in post-treatment tumor DNA in 3 out of 19 cases, invalidating these conclusions. However, with increased depth-of-sequencing, we still observed clonal loss in 16 cases (five with pTR). Using targeted genome sequencing of multiple sectors in a subset of cases, we were able to further validate clonal loss in two patients (Patients 15 and 16; both pTR-0). In three cases (Patients 5 [pTR-0], 10 [pTR-2], and 11 [pTR-0]), other sections showed persistence of clones that were originally

considered 'lost' by both WES and higher depth sequencing. Findings of tumor clonal loss by high-depth, multisector genome sequencing in some patients, including tumors with and without pTR, is further evidence of the anti-tumor effect of neoadjuvant pembrolizumab. However, we did not see a significant trend of clonal loss in patients with pTR. Thus, our findings strongly suggest that standard WES and calculated TMB from a single area, even if sampled from the same primary lesion before and after treatment, is not sufficient to make conclusions related to clonal dynamics due to insufficient sequencing depth and spatial heterogeneity. Furthermore, since we are often limited to a single, small biopsy from the lesion prior to treatment, these conclusions may be further influenced by spatial heterogeneity that was unevaluated at baseline.

Patients with pTR after neoadjuvant pembrolizumab had pre-existing primed immune effectors that were maintained over the course of treatment. pTR after neoadjuvant pembrolizumab correlated with baseline tumor PD-L1 expression, immune infiltrate, and IFN- γ pathway activity, but not with TMB. The lack of association of TMB and tumor response in our cohort may be due to limited patient numbers. In other cancers, tumor response to anti-PD-1 therapy correlated with TMB and with metrics which described the baseline T cell repertoire, infiltrating immune cell subpopulations and expression patterns related to their activity.(8,32–35)

Our study provides insights into mechanisms of intrinsic resistance to anti-PD1 therapy in patients with locally advanced HNSCC. Patients who did not experience pTR after neoadjuvant pembrolizumab showed limited immune activity in the baseline tumor specimen. A subset of these patients showed upregulation of immune pathways in the surgical sample after neoadjuvant pembrolizumab; however, this was counterbalanced by increased expression of T cell checkpoint molecules, including *PDCD1*, *CTLA4*, *ICOS*, *TIGIT*, *IDO1*, and *TNFSF4*. These observations show that one dose of neoadjuvant pembrolizumab promoted enhanced inflammatory gene signatures in some patients without pTR, and raise the possibility that additional doses of neoadjuvant pembrolizumab, or addition of therapy targeting different immune checkpoints, could increase the proportion of patients with pTR. In preclinical models, targeting immune checkpoint inhibitor compensatory responses enabled bypass of single immune checkpoint inhibitor resistance. (36,37) Importantly, it is also possible that a single dose of pembrolizumab induces an adaptive immune suppression. Note that 24/36 patients received only one dose of neoadjuvant pembrolizumab and 12/36 received neoadjuvant and adjuvant cycles. In melanoma, a single dose of neoadjuvant pembrolizumab in patients with stage IIIB/C or IV melanoma was predictive of clinical outcomes (17). Whether adaptive immune suppression is induced by neoadjuvant dosing or whether a single dose is predictive of clinical outcomes in HNSCC should be addressed in future trials defining the testing different numbers of doses in the neoadjuvant period.

After neoadjuvant pembrolizumab, we observed tumor down-staging in 19% of patients. Also, the rate of high-risk pathology (50%) was slightly lower than historical (68%). These outcomes were unexpected, and must be confirmed in prospective controlled trials. The importance of these observations is that they could alter recommendations for adjuvant therapy. The best example of the potential to alter adjuvant therapy recommendations was

patient 20, who presented with clinical stage IV (T2N2bM0) buccal SCC. After neoadjuvant pembrolizumab, the surgery specimen showed pathologic stage I (T1N0) disease. Extensive pTR was present, and only a 5 mm residual focus of carcinoma. In the absence of adjuvant therapy, the patient remained free of disease 29 months after surgery. Neoadjuvant immunotherapy has the potential to reduce the intensity of adjuvant therapy in patients with resectable, locally advanced HNSCC. However, our trial is limited in size as described below and this hypothesis needs rigorous validation in ongoing trials that evaluate and test the safety and/or efficacy of modifying standard of care adjuvant treatment paradigms when incorporating immunotherapy.

Our trial has several limitations. The patient sample size was small, and the study design did not include a placebo-controlled arm. The proportion of patients with high-risk pathology was lower than expected, which resulted in fewer patients given adjuvant pembrolizumab. The standard of care adjuvant therapy varied. We cannot conclude the safety or benefit of adjuvant pembrolizumab given the limited sample size. Due to the limited size of pre-treatment biopsies, we were unable to perform multisector, targeted genome sequencing in baseline tumor samples. Several biomarkers correlated with achievement of PTR to neoadjuvant pembrolizumab, but we were unable to address which biomarker was best suited to predict pTR. Relapse events through one-year after surgery were mature; however, longer follow-up is needed, because immunotherapy could delay the appearance of relapse events.

In conclusion, neoadjuvant pembrolizumab administered to patients with resectable locally advanced, HPV-unrelated HNSCC was safe, and resulted in pTR in 44% of patients and a one-year relapse rate lower than historical in patients with high-risk pathology. High-depth, multisector genome sequencing of surgical specimens documented tumor clonal loss after neoadjuvant pembrolizumab and highlighted the importance of accounting for spatial heterogeneity. Correlates of pTR with biomarkers of response and potential mechanisms of resistance to pembrolizumab were shown. Further studies of neoadjuvant pembrolizumab in patients with resectable locally advanced, HPV-unrelated HNSCC are warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

We thank all patients and their families for their participation in this study. We recognize the support of the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, the Clinical Trials Core, the Biostatistics Shared Resource, and the Center for Biomedical Informatics. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842. MG is funded by the National Human Genome Research Institute (NIH NHGRI R00HG007940), OLG by the National Cancer Institute (NIH/NCI K22CA188163, NIH/NCI U01CA209936 and NIH/NCI U24CA237719) and a Cancer Research Foundation Young Investigator Award. RU is funded by the National Institute for Dental and Craniofacial Research (NIH/NIDCR R01DE024403, R01DE027736) and a V Foundation Translational Research Award. Clinical trial support was through a Merck Investigator Studies Program award to RU/DRA.

Research Support: Merck, NCI, NIDCR, NHGRI and The V Foundation.

Declaration of Interests: RU is on the scientific advisory board at Merck. RIH receives research support and/or consults from BMS, Merck, Astra Zeneca, Pfizer, and Celgene. GJH receives research support and/or consults from

BMS, Merck, AstraZeneca, Pfizer, and Celgene. JS receives research support and/or consults from Bristol-Myers Squibb, Merck, AstraZeneca, Debiopharm, Nanobiotix, Regeneron and Tilos Therapeutics. RU and DA report research funding from Merck as part of the work under consideration for publication. DA reports personal fees for advisory role/consulting from Pfizer, Eli Lilly, Merck, Celgene, Cue Biopharma, and Loxo Oncology, and research funding from Pfizer, Eli Lilly, Merck, Celgene, Novartis, AstraZeneca, Atara, Blueprint Medicine, CellCeutix, Celldex, Enzychem, Gliknik, BMS, Kura, Medimmune, Exelixis, Innate, Matrix Biomed, and Polaris, outside the submitted work. EKB is a shareholder, executive, and a board member at Geneoscopy LLC. KMC is a shareholder in Geneoscopy LLC.

REFERENCES

1. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med. Massachusetts Medical Society*; 2004;350:1937–44.
2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. *N Engl J Med. Massachusetts Medical Society*; 2004;350:1945–52.
3. Harrington K, Temam S, Mehanna H, D’Cruz A, Jain M, D’Onofrio I, et al. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. *J Clin Oncol.* 2015;33:4202–9. [PubMed: 26527790]
4. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med. Massachusetts Medical Society*; 2016;375:1856–67.
5. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet.* 2019;393:156–67. [PubMed: 30509740]
6. Burtneß B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G, et al. LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) *Ann Oncol* [Internet]. Oxford University Press; 2018 [cited 2019 Mar 3];29 Available from: https://academic.oup.com/annonc/article/29/suppl_8/mdy424.045/5141840
7. Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. *Cancer Discov.* 2016;6:1382–99. [PubMed: 27663893]
8. Liu J, O’Donnell JS, Yan J, Madore J, Allen S, Smyth MJ, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. *Oncoimmunology.* 2019;8:e1581530. [PubMed: 31069141]
9. Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, et al. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. *Clin Cancer Res* [Internet]. 2019; Available from: 10.1158/1078-0432.CCR-19-2209
10. Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. *Oral Oncol.* 2017;73:65–9. [PubMed: 28939078]
11. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *N Engl J Med.* 2018;378:1976–86. [PubMed: 29658848]
12. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med.* 2018;24:1649–54. [PubMed: 30297909]
13. Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med.* 2018;24:1655–61. [PubMed: 30297911]
14. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial

Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol*. 2018;JCO1801148.

15. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. *Nat Med* [Internet]. 2019; Available from: 10.1038/s41591-018-0337-7
16. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. *Nat Med* [Internet]. 2019; Available from: 10.1038/s41591-018-0339-5
17. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nat Med* [Internet]. 2019; Available from: 10.1038/s41591-019-0357-y
18. Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. *Clin Cancer Res* [Internet]. 2020; Available from: 10.1158/1078-0432.CCR-19-3977
19. Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *J Clin Oncol*. 2020;JCO2000201.
20. Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. *Nat Med*. 2020;26:566–76. [PubMed: 32251400]
21. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–13. [PubMed: 15273542]
22. Mulder DT, Mahé ER, Dowar M, Hanna Y, Li T, Nguyen LT, et al. CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. *Blood Adv*. 2018;2:3506–14. [PubMed: 30530777]
23. Griffith M, Griffith OL, Smith SM, Ramu A, Callaway MB, Brummett AM, et al. Genome Modeling System: A Knowledge Management Platform for Genomics. *PLoS Comput Biol*. 2015;11:e1004274. [PubMed: 26158448]
24. Campbell KM, Lin T, Zolkind P, Barnell EK, Skidmore ZL, Winkler AE, et al. Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity. *Cell Rep*. 2018;24:2167–78. [PubMed: 30134176]
25. Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. *Genome Med*. 2016;8:11. [PubMed: 26825632]
26. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles *Nat Methods*. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved; 2015;12:453. [PubMed: 25822800]
27. Zhang L, Cham J, Paciorek A, Trager J, Sheikh N, Fong L. 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data. *BMC Bioinformatics*. 2017;18:129. [PubMed: 28241742]
28. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015;517:576–82. [PubMed: 25631445]
29. Xie C, Yeo ZX, Wong M, Piper J, Long T, Kirkness EF, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. *Proc Natl Acad Sci U S A*. 2017;114:8059–64. [PubMed: 28674023]
30. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell*. 2017;171:934–49.e15. [PubMed: 29033130]
31. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer Discov*. 2017;7:264–76. [PubMed: 28031159]

32. Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. *Clin Cancer Res.* 2016;22:2323–8. [PubMed: 26842238]
33. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *Br J Surg.* 2012;99:918–28. [PubMed: 22362002]
34. Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). *Ann Oncol.* 2018;29:1853–60. [PubMed: 29982279]
35. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol.* 2018;29:1861–8. [PubMed: 29945191]
36. Huang R-Y, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. *Oncoimmunology.* 2017;6:e1249561. [PubMed: 28197366]
37. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nat Commun.* 2016;7:10501. [PubMed: 26883990]

STATEMENT OF TRANSLATIONAL RELEVANCE

Many patients with locally advanced, human papillomavirus-unrelated HNSCC undergo multimodality therapy, including surgery followed by adjuvant (chemo-) radiation therapy. Outcomes are sub-optimal, especially for high-risk patients (positive margins and/or extra-nodal extension). Novel treatment intensification approaches are needed. As blocking monoclonal antibodies to the programmed death-1 (PD-1) pathway have improved patient outcomes across several cancer types, their integration into definitive surgical management is a logical next step. In this study, we completed a Phase II clinical trial with neoadjuvant and adjuvant pembrolizumab in HNSCC patients undergoing standard of care surgical therapy. We found this approach was safe in the surgical setting, identified pathologic changes induced by neoadjuvant pembrolizumab, defined pathologic and genomic biomarkers of response and potential for clinical impact. Together, these findings highlight pembrolizumab integration into the definitive surgical management of locally advanced HNSCC as a rational approach that warrants testing in the Phase III setting.




Figure 1. Trial profile and tumor responses (pathologic and radiologic) to neoadjuvant pembrolizumab

(A) Trial profile: Patients (n=36) with locally advanced, Stage III/IV, HPV-negative HNSCCs underwent baseline tumor and blood sampling and received neoadjuvant pembrolizumab 2–3 weeks before surgery. Of the 18 patients with high-risk pathology, 12 received adjuvant pembrolizumab. Patients with low/intermediate-risk pathology did not receive adjuvant pembrolizumab. (B) pathologic tumor response-2 (pTR-2) was observed in similar proportions of patients with low/intermediate and high-risk pathology. (C) Baseline and (D) post-neoadjuvant treatment (at surgery) images of oral cavity primary cancer in Patient 20 showing dramatic decrease in the size. (E) Representative CT images at baseline and (F) after neoadjuvant pembrolizumab (day prior to surgery), confirmed tumor response seen on physical exam. Notably, the pre-treatment CT and FDG-PET/CT scan (not shown) showed multiple large and necrotic FDG-avid neck lymph nodes, which are radiologic signs of SCC. Of note, the internal jugular vein (white arrow) was compressed on the baseline scan (E) and appeared fuller on the post-treatment scan (F). (G) Representative H&E slide of pTR highlighting changes noted in surgical specimens. (H) Nineteen patients had CT evaluations at baseline and prior to surgery following neoadjuvant pembrolizumab: 16 with stable disease (SD) and 3 with progressive disease (PD) by RECIST criteria. *Indicates two patients with pTR-1.




Figure 2. Pathologic tumor response correlates with tumor PD-L1 and immune infiltrates
 (A) Representative PD-L1 staining of tumor biopsies at baseline. (B) PD-L1 H-score correlated with pathologic tumor response (PTR). Baseline PD-L1 primary tumor expression levels by IHC and percent PTR were significantly positively correlated for 32 evaluated patients ($\rho=0.43$; 95%CI 0.079–0.668) (C) representative multiplex immunofluorescence (MIF) images showing patient 5 with minimal CD8+ T cell infiltrates and Patient 10 with higher CD8+ T cell infiltrates (white arrows) in baseline biopsies. (D) Extent of PTR was correlated with number of CD8+ T cells in the baseline biopsy tumor microenvironment (TME). Baseline number of TME CD8+ T cells assessed by MIF and percent PTR were significantly positively correlated for 23 evaluated patients ($\rho=0.72$; 95%CI: 0.443–0.875).




Figure 3. Immune infiltrate and activity correspond to patient response

A. Heatmap shows genes (n=41) associated with hallmark gene sets (right panel) that were differentially expressed ($p < 0.01$, adjusted $p < 0.25$) between patients with PTR and those without at baseline. Genes are sorted first by hallmark geneset, then by Ward’s hierarchical clustering. Patients are sorted by decreasing maximum PTR (at either the tumor or lymph node site), then by Ward’s hierarchical clustering. Expression is displayed as the gene-normalized expression across samples. **B–C.** Baseline- and post-treatment RNA was assessed for patterns of infiltrating immune cells, and values were summarized by the absolute levels of immune cells. These are indicated as the sum of all immune cell populations (Absolute score) or by subpopulation at baseline (B). Matched samples were available for a subset of patients (n=15) and the changes over the course of treatment are depicted by connected lines between baseline and resection timepoints in (C). Wilcoxon tests were used to evaluate statistical significance across responder groups and timepoints; *

indicates $p < 0.05$. **D.** Expression (Log2 FPKM, y-axis) of six genes in baseline and post-treatment bulk tumor RNAseq data. Points and lines are colored by either PTR (pTR-1/2) or without (pTR-0). Paired samples per individual are connected by lines, and p-values (labeled above) indicate the comparison of paired pre- and post-treatment samples.




Figure 4. Tumor mutational burden and neoantigen burden does not positively correlate with PTR

(A) The number of nonsilent mutations or (B) putative neoantigens predicted, as detected by WES and available RNAseq data from baseline samples (y-axes) was compared to the extent of PTR (x-axis). ‘Extent of PTR’ indicates the maximum PTR observed in the primary and/or resected lymph nodes. Points are colored by category of PTR, indicating whether there was no PTR (pTR-0), pTR-1 (<50% PTR at either site), or pTR-2 (>50% at either site).




Figure 5. Varied clonal dynamics due to spatial heterogeneity.

A) Clonality plots comparing VAF of SNVs and Indels at baseline (x-axis) and resection (y-axis). These values represent aggregate metrics of all post-treatment samples available, and colors represent variants that clustered together by comparing these aggregate metrics per individual. Open circles represent variants that were either unassigned or were assigned to clusters with less than 5 variants. **B)** The scaled allelic frequency (AF) is depicted on the y-axis of each variant (point) that was assigned a cluster in (A). The solid line represents the average scaled AF of the cluster. Shaded ribbons represent the standard error from the mean scaled AF of the cluster. Eight non-overlapping regions were isolated from Patient 2 post-treatment (PT) resected tumor, 7 regions were isolated from patient 10, and 8 regions were isolated from Patient 2 and analyzed (Supplementary Figure 10).

Table 1.

Patient Characteristics by Pathological Risk Category

Characteristic	All Patients (N=36)	Patients with High- Risk Pathology (N=18)	Patients with Low/ Int.-Risk Pathology (N=18)	p-value*	Diff (95% CI)
Age at enrollment (years)					
Median (range)	60 (32–87)	61.5 (37–87)	58.5 (32–73)	0.16	5 (–2 to 13)
Sex, N (%)					
Male	26 (72)	13 (72)	13 (72)	1.00	0 (–29 to 29)
Female	10 (28)	5 (28)	5 (28)		
Ethnicity, N(%)					
White	28 (78)	15 (83)	13 (72)	0.82	11 (–16 to 38)
Black	6 (17)	2 (11)	4 (22)		–11 (–35 to 13)
Asian	2 (5)	1 (6)	1 (6)		0 (–15 to 15)
Smoking history, N (%)					
Ever	31 (86)	16 (89)	15 (83)	1.00	6 (–17 to 28)
Never	5 (14)	2 (11)	3 (17)		
Smoking pack-years					
Median (range)	30 (0–80)	30 (0–80)	30 (0–80)	0.79	0 (–15 to 10)
Alcohol use history, N(%)					
Ever	23 (64)	11 (61)	12 (67)	1.00	–6 (–37 to 26)
Never	13 (36)	7 (39)	6 (33)		
ECOG Performance Status, N (%)					
0	26 (72)	16 (89)	10 (56)	0.06	33 (6 to 60)
1	10 (28)	2 (11)	8 (44)		
Tumor Site, N (%)					
Larynx/Hypopharynx	10 (28)	4 (22)	6 (33)	0.56	–11 (–4 to 18)
Oral Cavity	22 (61)	11 (61)	11 (61)		0 (–32 to 32)
Oropharynx	4 (11)	3 (17)	1 (6)		11 (–9 to 31)
Clinical T stage, N (%)					
T1–T2	7 (19)	4 (22)	3 (17)	0.59	5 (–20 to 31)
T3	4 (11)	3 (17)	1 (6)		11 (–9 to 31)
T4	25 (69)	11 (61)	14 (78)		–17 (–46 to 31)
Clinical N stage, N (%)					
N0–N1	13 (36)	2 (11)	11 (61)	0.005	–50 (–77 to 23)
N2	21 (58)	14 (78)	7 (39)		39 (9 to 68)
N3	2 (6)	2 (11)	0		11 (–3 to 26)
Clinical disease stage, N (%)					
III	3 (8)	0	3 (17)	0.23	–17 (–34 to 1)
IV	33 (92)	18 (100)	15 (83)		
Days First visit to surgery					
Median (range)	33 (25–76)	35 (25–76)	33 (25–58)	0.81	1 (–5 to 11)

Characteristic	All Patients (N=36)	Patients with High- Risk Pathology (N=18)	Patients with Low/ Int.-Risk Pathology (N=18)	p-value *	Diff (95% CI)
Days Neoadjuvant pembrolizumab to surgery					
Median (range)	16 (13–22)	16 (13–22)	18 (14–22)	0.23	–1 (–3 to 1)
Pathologic disease Stage, N (%)					
I–II	3 (8)	0	3 (17)	1.00	–17 (–34 to 1)
III	6 (17)	2 (11)	4 (22)		–11 (–35 to 13)
IVA–IVB	27 (75)	16 (89)	11 (61)		28 (10 to 55)

* Wilcoxon signed rank test used for continuous variables; Fisher's exact test used for categorical variables

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Neoadjuvant and adjuvant pembrolizumab-related adverse events

Event	Neoadjuvant Phase		Post-Surgery and Adjuvant Phase	
	All Patients (N=36)		Patients Treated with Adjuvant Pembrolizumab (N=12)*	
	Grades 1–2	Grades 3–4	Grades 1–2	Grades 3–4
	N (%)	N (%)	N (%)	N (%)
Fatigue	2 (6)	0 (0)	2 (17)	0 (0)
Hypothyroidism	0 (0)	0 (0)	3 (25)	1 (8)
Fever	1 (3)	0 (0)	0 (0)	0 (0)
Tumor flare	1 (3)	0 (0)	0 (0)	0 (0)
AST increase	0 (0)	0 (0)	1 (8)	0 (0)
ALT increase	0 (0)	0 (0)	1 (8)	0 (0)
Alk. Phos. increase	0 (0)	0 (0)	1 (8)	0 (0)
Diarrhea	0 (0)	0 (0)	1 (8)	0 (0)

* No post-surgery/adjuvant phase pembrolizumab-related adverse events occurred among patients who did not receive adjuvant pembrolizumab.